MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
Status:
Terminated
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well MK2206 works in treating patients with advanced
liver cancer that did not respond to previous therapy. MK2206 may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth.